Biohaven Ltd. (BHVN)
(Delayed Data from NYSE)
$36.72 USD
+0.21 (0.58%)
Updated May 24, 2024 04:00 PM ET
After-Market: $36.70 -0.02 (-0.05%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Biohaven Ltd. [BHVN]
Reports for Purchase
Showing records 41 - 60 ( 268 total )
Company: Biohaven Ltd.
Industry: Medical - Biomedical and Genetics
Weekly Neurology Prescription Sales Tracker -- Week Ending 3/4/22
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Biohaven Ltd.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Biohaven Ltd.
Industry: Medical - Biomedical and Genetics
Management Looks Beyond Migraine As Nurtec Continues to Deliver; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Biohaven Ltd.
Industry: Medical - Biomedical and Genetics
"Natural Born Killers" An Update in NK Cell Therapy
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Biohaven Ltd.
Industry: Medical - Biomedical and Genetics
Action-Packed 4Q21 Update - Addressing The Concerns
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Biohaven Ltd.
Industry: Medical - Biomedical and Genetics
Weekly Neurology Prescription Sales Tracker -- Week Ending 2/18/22
Provider: WEDBUSH SECURITIES INC.
Analyst: Research Department
Company: Biohaven Ltd.
Industry: Medical - Biomedical and Genetics
Company: Biohaven Ltd.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Biohaven Ltd.
Industry: Medical - Biomedical and Genetics
Company: Biohaven Ltd.
Industry: Medical - Biomedical and Genetics
Weekly Neurology Prescription Sales Tracker -- Week Ending 2/4/22
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Biohaven Ltd.
Industry: Medical - Biomedical and Genetics
Rx for Portfolios, Part 3: Commercial Launches Worth Keeping an Eye On
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Biohaven Ltd.
Industry: Medical - Biomedical and Genetics
Weekly Neurology Prescription Sales Tracker - Week Ending 1/21/22
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Biohaven Ltd.
Industry: Medical - Biomedical and Genetics
4Q21 Commercial Biotech Preview: Getting The Ducks In A Row
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Biohaven Ltd.
Industry: Medical - Biomedical and Genetics
Weekly Neurology Prescription Sales Tracker -- Week Ending 1/14/22
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Biohaven Ltd.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Biohaven Ltd.
Industry: Medical - Biomedical and Genetics
Weekly Neurology Prescription Sales Tracker -- Week Ending 1/7/22
Provider: WEDBUSH SECURITIES INC.
Analyst: Research Department
Company: Biohaven Ltd.
Industry: Medical - Biomedical and Genetics
Nurtec Rolls Into 2022 With Plenty of Momentum; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Biohaven Ltd.
Industry: Medical - Biomedical and Genetics
Just Keeps Running - BHVN Pre-Announces 4Q21/FY21 Nurtec ODT Beat
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Biohaven Ltd.
Industry: Medical - Biomedical and Genetics
Company: Biohaven Ltd.
Industry: Medical - Biomedical and Genetics
Weekly Neurology Prescription Sales Tracker - Week Ending 12/24/21
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L